期刊
ANTIBIOTICS-BASEL
卷 11, 期 8, 页码 -出版社
MDPI
DOI: 10.3390/antibiotics11081032
关键词
antimicrobial resistance; acne vulgaris therapy; tetracycline antibiotic adverse events; dermatologic skin disease; Cutibacterium acnes
Almost 1 billion people worldwide have acne, and oral tetracyclines are commonly prescribed for treatment. However, concerns about antibiotic resistance and side effects have arisen. Sarecycline, a narrow-spectrum tetracycline approved in 2018, shows promise in reducing resistance risk by targeting the pathogenic bacterium in acne vulgaris.
Almost 1 billion people worldwide have acne, and oral tetracyclines, including doxycycline and minocycline, are effective and frequently prescribed treatments for acne. However, there is growing concern for the development of antibiotic resistance with such widespread utilization by dermatologists. Additionally, tetracyclines are known to have various potential side effects, including gut dysbiosis, gastrointestinal upset, photosensitivity, dizziness, and vertigo. However, in 2018 a novel narrow-spectrum tetracycline, sarecycline, was Food and Drug Administration-approved to treat moderate-to-severe acne vulgaris in patients 9-years-old and above. Sarecycline was designed to target Cutibacterium acnes, the pathogenic bacterium in acne vulgaris, which may reduce the risk of resistance. This paper examines the growing concerns of antibiotic resistance due to oral tetracycline usage in the treatment of acne vulgaris, with a focus on the promising third-generation, narrow-spectrum tetracycline, sarecycline.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据